Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Cystic Fibrosis
Interventions
DRUG

ELX/TEZ/IVA

Fixed-dose combination granules for oral administration.

DRUG

IVA

Granules for oral administration

Trial Locations (18)

Unknown

The Kids Research Institute Australia, Nedlands

The Royal Children's Hospital, Parkville

Queensland Children's Hospital, South Brisbane

The Hospital for Sick Children, Toronto

British Columbia Children's Hospital, Vancouver

Juliane Marie Center, Rigshospitalet, Copenhagen

Charité Universitätsmedizin BerlinX, Berlin

Kinderklinik III, Abt. fur Pneumologie, Essen

Medizinische Hochschule Hannover, Hanover

Erasmus Medical Center, Rotterdam

Inselspital - Universitaetsspital Bern, Bern

Kinderspital Zurich, Zurich

Children and Young Adults Research Unit, Cardiff

Leeds General Infirmary, Leeds

Alder Hey Children's NHS Foundation Trust, Liverpool

Great Ormond Street Hospital for Children, London

Royal Brompton Hospital, London

Southampton General Hospital, Southampton

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06460506 - Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | Biotech Hunter | Biotech Hunter